The hearing that could help decide marijuana's federal future just got its guest list, and it reads like a roll call of the legalization movement's oldest opponents. With the DEA's rescheduling hearing set to begin June 29, the agency has released the roster of who will actually get to testify — and every selected participant is an opponent of cannabis reform. The roughly $30 billion U.S. cannabis industry, patient advocates, and legalization groups were all shut out.
Who's in the room
According to the list the DEA published, the parties cleared to participate are:
- Smart Approaches to Marijuana (SAM) — the country's most organized anti-legalization group
- The National Drug & Alcohol Screening Association — the drug-testing industry
- The states of Nebraska, Idaho, Indiana, and Louisiana
- The Tennessee Bureau of Investigation
- DUID Victim Voices
- Two individuals, Kenneth Finn, MD and Phillip A. Drum, PharmD
That's the whole list. SAM, whose CEO Kevin Sabet called rescheduling "the greatest drug policy mistake in a generation," said it "looks forward to presenting the science, the data, and the public health stakes that demonstrate why rescheduling should be rejected." Notably, SAM's political arm is also bankrolling a Massachusetts ballot measure to end adult-use sales there.
Why the industry got rejected
The exclusions aren't a glitch — they're the legal design. Under federal rules, only parties "adversely affected or aggrieved" by a proposed policy change qualify as "interested parties" in this kind of administrative hearing. Reform advocates and the industry, by definition, support rescheduling, so they don't fit the "aggrieved" standard. The DEA sent rejection notices late last week to applicants including the American Trade Association for Cannabis and Hemp (ATACH) and the American Council for Cannabis Medicine.
ATACH president Michael Bronstein called his group's exclusion "a missed opportunity" and described the final roster as "a who's who of prohibitionist voices who have little-to-no experience with the medical use of cannabis."
The counterintuitive read
Here's where seasoned observers diverge from the outrage. A few voices argue this might not be the disaster it looks like. With only opponents in the room, the DEA itself effectively has to defend the rescheduling it ordered — and a shorter, one-sided participant list could actually move the proceedings along faster rather than bogging them down in adversarial cross-examination.
"This would be considered the expected outcome," said Doug Benns of the American Council for Cannabis Medicine, whose own application was rejected. "A lot of us were considered longshots... They are trying to hear from the opposition." In other words: the agency may be assembling the case against rescheduling precisely so it can rule past it.
It's a glass-half-full theory, and it may be wishful. But it's a reminder that the optics of an opponent-only hearing don't automatically dictate the outcome.
What's actually on the table
It's worth being precise about the stakes, because they're bigger than the medical reclassification already in effect. The hearing will weigh the broader proposal to move all marijuana to Schedule III — the Biden-era recommendation — not just the medical-only downgrade that took effect in April. That distinction is the heart of the matter: right now the country runs a two-tier federal system, with medical cannabis at Schedule III and adult-use still on Schedule I.
As Connecticut's cannabis ombudsman Erika Gorman Kirk put it, that split "does not give the supply chain something to stand on — it gives them a fault line to fall through." Resolving it is what June 29 is really about, and the participant list, she noted, "suggests the DEA would prefer not to hear it out loud."
The bigger picture
This is the latest twist in a saga we've been tracking closely, from the court challenge seeking to freeze rescheduling to NORML's push to get consumers a seat at the table — a request that, per this list, was denied. It also lands the same month the industry notched a genuine milestone with Trulieve's NYSE debut, a reminder that the federal picture is moving in two directions at once: real progress on one hand, an opposition-stacked hearing on the other.
The bottom line
The DEA will spend late June listening exclusively to cannabis reform's critics as it weighs the plant's federal future — a roster that's either a procedural formality or a thumb on the scale, depending on who you ask. Either way, the decision that follows will ripple through taxes, research, banking, and the legal status of the entire adult-use market. The opponents got the microphone; now the industry waits to see whether the outcome listens to anyone else. For adults 21+.